Summary of "FRCPath Part 2: Series 1, Lecture 2: By Dr Ahmed Ali"

Main ideas / lessons from the lecture (FRCPath Part 2, Breast Pathology)

1) Core biopsy reporting: screening vs symptomatic/imaging-detected cases

• Key UK exam concept: A breast core biopsy can be from:
  • Screening programs → often many cases show breast microcalcifications, leading to lots of “benign/low-risk” descriptive findings.
  • Clinical presentation (lump/skin change/heaviness) or incidental imaging finding → may also prompt biopsy, but the emphasis differs.
• Critical pitfall in exams (b-categories):
  • If a case is selected due to microcalcification, you must not ignore that request/history in your final categorization.
  • In England-style categorization, microcalcification-associated lesions should be assigned with the appropriate B-category; the lecturer specifically warns that failing to reflect microcalcification correctly can fail the case.
• Where to learn the B-category approach:
  • Lecturer points to datasets on the College/website:
    • One dataset for core biopsies
    • Another for resections (macro stage)

2) B-category framework for breast core biopsies (as taught here)

• The lecturer uses England-style categories: B1–B5, with emphasis that B3 is central to radial scar uncertainty.
• General exam takeaway: don’t force a single “final named diagnosis” when using core biopsy criteria; instead, use descriptive reporting and appropriate categorization.
• B3 significance in this lecture:
  • Radial scar on core biopsy is commonly categorized as B3 due to associated risks found on excision (covered later).

3) Radial scar: morphology, why it’s an exam “nightmare,” and why it often becomes B3

Why radial scar causes problems in exams

• More tissue to interpret and limited time (lecturer reiterates typically ~2 minutes to write findings).
• Sampling limitation: biopsy sampling may not show the lesion’s full architecture.

Morphological points emphasized

• On excision (usually easier):

  • Look for central scar fibrosis
  • Irradiating fibrous tissue with a circumferential “radiating” pattern

• On biopsy (harder because of partial sampling):

  • You may only see the edge
  • Key warning: fibrous bundles/finger-like extensions should go around tubules and lobules (a nuance many textbooks under-describe)

• The lecture stresses don’t misinterpret what looks like sclerosing adenosis:

  • Radial scar areas can show complex ductal and lobular-looking differentiation
  • Apparent duct branching/budding and lobule formation can mislead you toward sclerosing adenosis

4) “Don’t diagnose too early”: descriptive reporting + avoid premature single-label certainty

• The lecturer repeatedly advises:
  • If unsure, write what you see (descriptive detail).
  • Avoid tying everything to one named diagnosis (e.g., “just closing/sclerosing adenosis”).
• Rationale: core biopsies are often intermediate/uncertain lesions, and the exam expects structured reasoning and correct categorization.

5) Radial scar associations that drive B3 categorization

The “triad” and linked lesions emphasized

• On radial scar sampling, excision may reveal additional pathology more often because of increased sampling.
• Exam-relevant triad highlighted:
  • Radial scar
  • Columnar cell change (and related abnormalities)
  • Tubular carcinoma

Additional associated lesions to actively search for

• Tubular carcinoma
• DCIS
• Lobular neoplasia
• Columnar cell change

Practical instruction: search strategy

When radial scar appears on a core biopsy:

• Actively search carefully for:
  • tubular carcinoma
  • DCIS
  • lobular neoplasia
  • columnar cell change

This links directly to why B3 is used: adjacent malignancies can be missed unless you actively look.

Correlation vs causation (lecturer’s nuance)

• The lecture emphasizes the association may be related to frequent sampling, not necessarily that radial scar itself directly causes cancer.

6) Columnar cell change: recognition and what not to miss

• Columnar cell change shows:
  • lining changes with snouting/apical morphology
  • often dilated ducts
• Key caution:
  • Columnar cell change can overlap with lesions across the malignancy spectrum
  • Ensure you don’t miss low-grade tubular carcinoma adjacent to columnar cell change
• “Don’t overreact” tip:
  • Very small ducts can make assessing columnar change hard—interpret cautiously rather than getting stuck.

7) Differentiating sclerosing adenosis vs tubular carcinoma (core biopsy problem)

Main exam challenge

Differentiation is difficult because:

• inability to clearly define lobular architecture
• ducts/glands may span the core
• sampling artifacts

Suggested step-by-step approach from the lecture

1. Identify the “center” of the lesion
   • Choose where the larger glands/ducts are most prominent.
2. Assess glands/ducts from center to periphery
   • Sclerosing adenosis: tends to show ductal collapse/changes at periphery (less “open” gland appearance).
   • Tubular carcinoma: ducts may remain more patent/open peripherally and show uniformity.
3. Assess myoepithelial cell presence
   • Must be convinced (don’t “imagine” them).
   • Tubular carcinoma: should show absence of myoepithelial cells around involved glands.
   • Microglandular-type benign diagnoses should not show myoepithelial loss.
4. Consider gland size/cell size differences
   • Malignant glands/cells are typically about ~2× or more larger than background ducts (lecturer references ~two to two-and-a-half times).
5. Check duct shape features (with caveats)
   • Tubular carcinoma may show more irregular/angulated ducts, but sectioning can make angulation hard to judge.
6. Use immunohistochemistry when in doubt
   • Lecturer explicitly states immuno is required; making a diagnosis “without immuno” is described as “madness.”
   • UK myoepithelial markers mentioned:
     • p63
     • CK5 / CK5-6 (lecturer notes some use CK14; traditional use noted as CK5)

Conclusion rule (exam confidence):

• In uncertain cases between sclerosing adenosis/complex lesion vs tubular carcinoma, the lecturer still expects differentiation using immuno, and provides an “exam writing template” approach (see MDT/exam strategy below).

8) What to include for tubular carcinoma-type cases (extra marking points)

The lecturer lists typical “what examiners expect” items (especially for management-style scoring):

• Measure lesion size
• Provide TNM classification
• If margins are involved/examined:
  • Distance to inked margin
• Grade the tumor
• Include relevant patient context when asked (e.g., family history)
• Discuss MDT decision-making (see next section)
• Notes on nodal risk/prognosis (as stated):
  • Tubular carcinoma is unlikely to have a positive sentinel lymph node and has good prognosis (though sentinel node may still be performed).

9) Molecular testing / BC/BRCA and related exam station themes

• Lecturer warns some stations focus on molecular testing knowledge.
• Examples mentioned:
  • BRCA testing (breast context; also other related molecular questions)
  • EGFR (lung adenocarcinoma)
  • MSI (associated with certain adenoma/traditional serrated contexts mentioned)

10) MDT (multidisciplinary team) writing strategy: how to score marks

What MDT means (UK context)

• Regular cancer meeting involving specialties (e.g., oncologists, surgeons) to plan management.

How to score marks

• State the case will be discussed at MDT
  • This gives points.
• Add brief “why,” such as:
  • discussing completeness of excision
  • discussing further management plan

If unsure: use an exam-safe descriptive template

Lecturer recommends a composed structure (not panic), e.g.:

• “Irregular ductal proliferation…”
• “Uncertainty about presence/interpretation of myoepithelial cells…”
• Differential between sclerosing adenosis/complex lesion and tubular carcinoma
• Plan: “I will do immunohistochemistry for myoepithelial markers…”
• You may state “favored” while acknowledging uncertainty if you explicitly state differentiation intent.

11) Exam practice methodology emphasized (timing + written approach)

Timing practice

• Practice specifically for 8 minutes (lecturer’s marking-format advice).
• Don’t only practice for 10 minutes—time overruns can occur due to exam distractions.

Writing structure suggestion

• If confident, start with the diagnosis.
• Leave a page space, then write in structured order:
  • Diagnosis
  • Differential
  • Additional work
  • Additional information
• Quick review of microsections/microscopy portion last, since microscopy carries weight.

---

Speakers / sources featured (as named in the subtitles)

Speaker(s)

• Dr Ahmed Ali (main lecturer)

Other sources / websites / systems mentioned

• College / UK breast pathology datasets
  • Two datasets: one for core biopsies, one for resections
• PathPresenter website
• Leeds virtual histopathology website
• U.S. CAP (mentioned generally as a focus source)
• Exam formats / FRCPath Part 2 stations (generic)
• Publication by “Jason” (referenced as showing correlation rather than direct causation; full citation not provided)

Category

Educational

---

Share this summary

Share on X/Twitter Share on Facebook Share on LinkedIn Share on Reddit Share on WhatsApp Share on Telegram

---

Is the summary off?

If you think the summary is inaccurate, you can reprocess it with the latest model.

Reprocess summary

Video